Could a common vitamin a drug tame a deadly immune storm?
NCT ID NCT07626398
First seen Jun 09, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tests a drug called all-trans retinoic acid (ATRA) as a first treatment for hemophagocytic lymphohistiocytosis (HLH), a rare but life-threatening condition where the immune system goes into overdrive. ATRA is an oral medication already used for other blood diseases and may calm the immune response with fewer side effects than current harsh treatments. About 30 adults with newly diagnosed or untreated active HLH will receive ATRA, and researchers will check if it improves symptoms and blood markers at 4 and 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.